MX2021004386A - Novel compounds. - Google Patents
Novel compounds.Info
- Publication number
- MX2021004386A MX2021004386A MX2021004386A MX2021004386A MX2021004386A MX 2021004386 A MX2021004386 A MX 2021004386A MX 2021004386 A MX2021004386 A MX 2021004386A MX 2021004386 A MX2021004386 A MX 2021004386A MX 2021004386 A MX2021004386 A MX 2021004386A
- Authority
- MX
- Mexico
- Prior art keywords
- novel compounds
- formula
- compound
- novel
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
A compound of formula (I): (Formula (I)) and related aspects.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18200626 | 2018-10-16 | ||
| PCT/GB2019/052937 WO2020079422A1 (en) | 2018-10-16 | 2019-10-16 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004386A true MX2021004386A (en) | 2021-06-04 |
Family
ID=63878368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004386A MX2021004386A (en) | 2018-10-16 | 2019-10-16 | Novel compounds. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3867247A1 (en) |
| JP (1) | JP7465868B2 (en) |
| KR (1) | KR20210076081A (en) |
| AR (1) | AR116713A1 (en) |
| AU (1) | AU2019360017A1 (en) |
| BR (1) | BR112021006940A2 (en) |
| IL (1) | IL282096B1 (en) |
| MX (1) | MX2021004386A (en) |
| TW (1) | TWI827706B (en) |
| WO (1) | WO2020079422A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021156584A1 (en) * | 2020-02-06 | 2021-08-12 | Autifony Therapeutics Limited | Kv3 modulators |
| KR20240046538A (en) | 2021-08-09 | 2024-04-09 | 얀센 파마슈티카 엔브이 | Monoacylglycerol lipase modulators for use in autism spectrum disorders |
| CN117751119A (en) | 2021-08-10 | 2024-03-22 | 奥蒂福尼疗法有限公司 | Potassium channel modulators |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA019970B8 (en) | 2009-12-11 | 2014-11-28 | Отифони Терапеутикс Лимитед | Imidazolidinedione derivatives |
| BR112013013914B1 (en) * | 2010-12-06 | 2021-10-26 | Autifony Therapeutics Limited | HIDANTOIN DERIVED COMPOUNDS USEFUL AS KV3 INHIBITORS, USES OF SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITION INCLUDING THEM |
| WO2012168710A1 (en) | 2011-06-07 | 2012-12-13 | Autifony Therapeutics Limited | Hydantoin derivates as kv3 inhibitors |
| GB201209986D0 (en) | 2012-06-06 | 2012-07-18 | Autifony Therapeutics Ltd | Novel compounds |
| KR20140098850A (en) | 2011-12-06 | 2014-08-08 | 오티포니 세라피틱스 리미티드 | Hydantoin derivatives useful as kv3 inhibitors |
| BR112014028718A2 (en) | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | hydantoin derivatives as kv3 inhibitors |
| EP2852589B1 (en) | 2012-05-22 | 2021-04-28 | Autifony Therapeutics Limited | Triazoles as kv3 inhibitors |
| WO2013182851A1 (en) | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201522179D0 (en) | 2015-12-16 | 2016-01-27 | Autifony Therapeutics Ltd | Novel compounds |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| US20200039970A1 (en) | 2016-12-16 | 2020-02-06 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
-
2019
- 2019-10-16 BR BR112021006940-2A patent/BR112021006940A2/en unknown
- 2019-10-16 KR KR1020217014348A patent/KR20210076081A/en active Search and Examination
- 2019-10-16 EP EP19790048.3A patent/EP3867247A1/en active Pending
- 2019-10-16 MX MX2021004386A patent/MX2021004386A/en unknown
- 2019-10-16 WO PCT/GB2019/052937 patent/WO2020079422A1/en active Application Filing
- 2019-10-16 TW TW108137290A patent/TWI827706B/en active
- 2019-10-16 IL IL282096A patent/IL282096B1/en unknown
- 2019-10-16 AU AU2019360017A patent/AU2019360017A1/en active Pending
- 2019-10-16 AR ARP190102939A patent/AR116713A1/en unknown
- 2019-10-16 JP JP2021521058A patent/JP7465868B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW202035394A (en) | 2020-10-01 |
| EP3867247A1 (en) | 2021-08-25 |
| AR116713A1 (en) | 2021-06-02 |
| BR112021006940A2 (en) | 2021-07-13 |
| IL282096B1 (en) | 2024-03-01 |
| TWI827706B (en) | 2024-01-01 |
| WO2020079422A1 (en) | 2020-04-23 |
| IL282096A (en) | 2021-05-31 |
| AU2019360017A1 (en) | 2021-04-01 |
| KR20210076081A (en) | 2021-06-23 |
| JP2022505143A (en) | 2022-01-14 |
| JP7465868B2 (en) | 2024-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500655A1 (en) | Compounds | |
| PH12020500673A1 (en) | Compounds | |
| MX2020009347A (en) | Picolinamides as fungicides. | |
| PH12018501099A1 (en) | Novel biphenyl compound or salt thereof | |
| AU2016277367A8 (en) | Aryl sulfonohydrazides | |
| PH12015502031B1 (en) | Tetrahydropyrrolothiazine compounds | |
| PH12019500664A1 (en) | New isoxazolyl ether derivatives as gaba a alpha5 pam | |
| MX2020009234A (en) | Heteroaryl compounds as type ii irak inhibitors and uses hereof. | |
| MX2021004386A (en) | Novel compounds. | |
| MX2020014097A (en) | Novel lipids. | |
| SG10201805896SA (en) | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS | |
| GEP20227389B (en) | Microbiocidal thiazole derivatives | |
| CR20220117A (en) | Heterocyclic compounds | |
| MY193239A (en) | Novel b-lactamase inhibitors | |
| MX2015015841A (en) | Phenoxyethyl dihydro-1h-isoquinoline compounds. | |
| MX2021001904A (en) | Solid forms of substituted benzoxaborole and compositions thereof. | |
| WO2018091964A8 (en) | Process for preparing methoxy methyl pyridine dicarboxylate | |
| IN2014MU00195A (en) | ||
| EA202190989A1 (en) | A NEW METHOD FOR THE SYNTHESIS OF PIPERAZINYL-ETHOXY-BROMPHENYL DERIVATIVES AND THEIR APPLICATION IN THE PREPARATION OF THEIR COMPOUNDS | |
| MX2020007342A (en) | Silylethynyl hetaryl compounds as nitrification inhibitors. | |
| MX2021009261A (en) | Fluorovinylbenzamide compound as pd-l1 immunomodulator. | |
| IN2014MU00194A (en) | ||
| MX2022006984A (en) | Process and intermediate for the preparation of oxetan-2-ylmethanamine. | |
| MX2022006776A (en) | Ophthalmic pharmaceutical compositions. | |
| MX2023002525A (en) | Novel compounds. |